The nuclear Ferredoxin reductase and its role in tumor suppression
- Institution
- UNIVERSITY OF CALIFORNIA AT DAVIS, CA
- Principal investigator
- Xinbin Chen
- Funding
- $480K
- Duration
- 2024–2029
Moonbase score
Still being scored
Abstract
Project Summary/Abstract We and others showed that ferredoxin reductase (FDXR), a mitochondrial flavoprotein, is induced by DNA damage in a p53-dependent manner and regulates apoptosis induced by reactive oxygen species. As the only human ferredoxin reductase, FDXR receives two electrons from NADPH and transfers them one at a time to its cognate substrates ferredoxin 1 (FDX1) and FDX2 and subsequently, plays a role in biogenesis of steroids and iron sulfur cluster proteins. Despite these well-defined biochemical functions, the role of FDXR in tumor suppression is still poorly understood. Interestingly, recent studies showed that FDXR is the most consistent acute sensor following DNA damage, suggesting that FDXR plays a role in DNA damage response and repair. Indeed, our pilot studies showed that FDXR is also expressed in the nucleus and regulates cell growth and survival potentially via its nuclear substrates (p53, Mdm2, and Mdm4) in response to a stress. These observations prompt us to hypothesize that the nuclear FDXR has a critical biological function in tumor suppression. To further test this, two specific aims are proposed: (1) To determine how FDXR subcellular localization is regulated; (2) To determine how the nuclear FDXR exerts its biological function.
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF CALIFORNIA AT DAVIS
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · University of California at DavisNot yet scored
A novel therapeutic strategy to target mutant p53
Xinbin Chen · $591K · 2025–2030
- NIH · University of California at DavisNot yet scored
The Mechanism and Therapeutic Potential of Targeting the Ninjurin Pathway for Tumors Carrying Wild-Type p53
Xinbin Chen · $437K · 2022–2027
- NIH · University of California at DavisNot yet scored
Comparative Oncology Program
Xinbin Chen · $74K · 2002–2026